Biotech Values

[rfj1862]

VKTX FYI

I have no idea who has a little VKTX but the conference call was interesting last night.

Phase 2B results for the TRbeta agonist still anticipated for 1H2023
Results for the GLP-1/GIP agonist coming before end of Q12023. I was mostly thinking about this as a sideshow but analysts are weirdly excited about it?
Results for the X-ALD program due 2H2023

$155 million in the bank so no dilution in the foreseeable future (meaning at least 2 years)

They are actively seeking partners for the NASH program, which of course is an enormous market.

Editorial comment: I think this may have the best risk:reward in the biotech universe right now because their molecule is similar to that of MDGL's and is thus de-risked to the extent that a novel molecular entity can be. The company has a market cap that is roughly 1/3rd that of AKRO, which has a demonstrably inferior drug and no pipeline to speak of. And I guess based on all the excitement last night about the GLP-1/GIP agonist there is significant value there too despite it being early? I don't know why they were so interested in it.

*Edited, I accidentally said that the results for the dual agonist will be from a 2B trial -- that's the TRbeta agonist (sorry)